Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
What's New in Topical Therapy?
Description
The presentation discusses advancements in topical therapies, emphasizing a shift in treatment approaches for skin conditions such as atopic dermatitis and psoriasis. The speaker, affiliated with the Henry Ford Health System, highlights the common confusion among patients regarding the use of various topical steroids and the need for clearer treatment regimens. New non-steroidal topical options, including rexalidinib, to pin her off, riflumalast, and delgasidinib are introduced, showcasing their efficacy and improved tolerability compared to traditional treatments. Rexalidinib, now FDA approved for atopic dermatitis in patients aged 12 and older, demonstrates rapid effectiveness and good long-term outcomes, even in children. To pin her off and riflumalast also show promising results for psoriasis and atopic dermatitis, including in sensitive areas like the face and hands. Furthermore, new formulations, such as riflumalast foam, are effective for seborrheic dermatitis. These advancements aim to simplify patients' treatment regimens and improve overall disease management. The speaker concludes that while new non-steroidal options are valuable, topical steroids will continue to play a significant role in treatment.
View moreConclusions
- Patients often do not understand how to correctly use their topical therapies, leading to confusion and poor outcomes.
- New non-steroidal topical options, like ruxolitinib and roflumilast, can effectively simplify treatment regimens for patients.
- Ruxolitinib cream has shown to be effective in treating atopic dermatitis and psoriasis, with a favorable side effect profile.
- Roflumilast also demonstrates efficacy for psoriasis and atopic dermatitis, particularly in sensitive areas, with good patient tolerability.
- Both ruxolitinib and roflumilast offer quicker relief from symptoms like itching and have demonstrated substantial improvement in skin condition over time.
- Patients can experience long periods of disease control after treatment with these new therapies, reducing reliance on chronic medications.
- Delgocitinib shows promising results for chronic hand eczema, achieving significant clinical improvements and a comparable safety profile to existing therapies.
- Overall, the introduction of these new treatments provides effective alternatives to traditional topical steroids, enhancing patient care in dermatology.
- Papp K, et al. Presented at 2nd Annual Revolutionizing Atopic Dermatitis Conference; April 4-6, 2020; Chicago, IL.
- Armstrong A, Eichenfield LF, Lee LW. Efficacy of Ruxolitinib Cream for Treatment of Atopic Dermatitis in Children Aged 2 to 11 Years by Baseline Clinical Characteristics: Subgroup Analysis From a Randomized Phase 3 Study (TRuE-AD3). Poster presented at: American Academy of Dermatology (AAD) Annual Meeting; March 8-12, 2024; San Diego, CA.
- Smith SH et al. J Inv Dermatol. 2017;137:2110-2119;
- Furue M, et al. J Dermatological Sci. 2015;80:83-88;
- Tsuji G, et al. J Invest Dermatol. 2012;132:59-68;
- Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. N Engl J Med. 2021 Dec 9; 385(24):2219-2229.
- Strober B, Stein Gold L, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial. J Am Acad Dermatol. 2022 Oct;87(4):800-806.
- Lebwohl MG, Kircik LH, Moore AY, Stein Gold L, et al. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials. JAMA. 2022 Sep 20;328(11):1073-1084.
- Capucci S, et al. Dermatitis. 2020 May/Jun; 31 (3): 178-184.
- Thyssen JP, et al. Contact Dermatitis. 2022 May; 86 (5): 357-378.